Dr. Michael Nissen and Dr. Firas Rahhal, though fully occupied with busy Vitreoretinal Surgery practices in New York City and Los Angeles, noticed a significant shift in the Ophthalmology and eye care industry over the last several years. A portion of previously untreatable diseases were suddenly treatable, preventing vision loss in many patients. For the first time in their twenty-five year careers, the doctors were able to tell patients that there was real hope of curing many damaging, and sometimes blinding, eye diseases. The shift was due to a fundamental change in the eye care space; the development of the science and technology necessary to create novel and effective treatments for serious eye diseases had reached the critical mass necessary to create truly meaningful treatments and cures. Contributing to this trend were advances in drug development coupled with technologic advancements in basic science and engineering that allowed development of superior, smaller, safer, and more effective surgical tools and diagnostic equipment. These advances were almost all industry sponsored and proprietary with heavy involvement from the private financial community. The rate of development of new treatments and procedures is now increasing at an exponential rate driven by increasingly powerful and accessible technology. The timing is propitious as a number of contributing factors are driving a global spike in the demand for eye care. Doctors and researchers, encouraged by the success of ground-breaking entrepreneurs in the eye care space, were bringing ideas to Dr. Nissen and Dr. Rahhal who realized that the moment had come to increase their impact beyond that of treating several hundred patients per week. Randy Cohen, Adam Benowitz, and Alan Spiro recognized the same moment from the perspective of eye patients afflicted by serious eye diseases. All three are benefactors of important eye care foundations. James Murray and Maneesha Ghiya were recruited as investment professionals and ExSight Capital was born.